Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobin

5 Oct 2007

Abstract excerpt

5-azacytidine (5-Aza) is a potent inducer of fetal hemoglobin (HbF) in people with beta-thalassemia and sickle cell disease. Two models have been proposed to explain this activity. The first is based on the drug's ability to inhibit global DNA methylation, including the fetal globin genes, resulting in their activation. The second is based on 5-Aza's cytotoxicity and observations that HbF production is enhanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Hemoglobinopathies and Related Disorders
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17916742
DOI: 10.1182/blood-2007-06-093948

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobinPMID 17916742Read ↗

Developmental- and differentiation-specific patterns of human γ- and β-globin promoter DNA methylationSemantic proximity Read ↗

Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell diseaseSemantic proximity Read ↗

Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemiaSemantic proximity Read ↗

Fetal hemoglobin induction in azacytidine responders enlightens methylation patterns related to blast clearance in higher-risk MDS and CMMLSemantic proximity Read ↗

Inactivation of HDAC 1 or HDAC 2 induces gamma globin expression without altering cell cycle or proliferationSemantic proximity Read ↗

Fetal hemoglobin silencing in humansSemantic proximity Read ↗

A natural DNMT1 mutation elevates the fetal hemoglobin level via epigenetic derepression of the γ-globin gene in β-thalassemia.Semantic proximity Read ↗

Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemiaSemantic proximity Read ↗

MIR 29B mediates epigenetic mechanisms of HBG gene activationSemantic proximity Read ↗

Enhanced induction of fetal hemoglobin by the combination of decitabine with RN-1 in β-thalassemia/HbE erythroid progenitor cells.Semantic proximity Read ↗

Reviewing the impact of hydroxyurea on DNA methylation and its potential clinical implications in sickle cell diseaseSemantic proximity Read ↗

Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.